Deal title |
Principal company |
Partner company |
Total projected at signing (US$M) |
Start date |
January | ||||
Shire to develop AB Biosciences' PRIM program using oligomeric Fc technology for autoimmune and other immune-mediated disorders worldwide |
AB Biosciences Inc. |
Shire plc |
Payment unspecified |
1/30/18 |
Akeso and THB to develop AK-103 for cancer |
Akeso Biopharma Inc. |
Taizhou Hanzhong Biomed Co. Ltd. |
Unknown |
1/29/18 |
Romastru to distribute Amryt's Lojuxta against homozygous familial hypercholesterolemia in Romania and Bulgaria |
Amryt Pharma plc |
Romastru Trading SRL |
Payment unspecified |
1/30/18 |
NCPC Genetech to develop and commercialize CJ's darbepoetin alfa biosimilar against chronic renal anemia in China |
CJ Healthcare Corp. |
NCPC Genetech Biotechnology Development Co. Ltd. |
Payment unspecified |
1/30/18 |
DNA Script to use Dynamic's DNA building block for use in synthetic DNA and other nucleic acid synthesis |
Dynamic Combinatorial Chemistry LLC |
DNA Script |
Payment unspecified |
1/30/18 |
Xoma to acquire intellectual property assets related to a PD-1 antibody program from Enumeral Biomedical |
Enumeral Biomedical Holdings Inc. |
Xoma Corp. |
$1.60 |
1/26/18 |
Stemonix to conduct research on Humanetics' BIO-300 for radiation-induced cardiovascular disease |
Humanetics Corp. |
Stemonix Inc. |
Payment unspecified |
1/30/18 |
Elpis Biomed to acquire iPS Academia's patents related to iPS cell technologies |
iPS Academia Japan Inc. |
Elpis Biomed Ltd. |
Payment unspecified |
1/29/18 |
Metrion to acquire JT's portfolio of potassium channel inhibitors for autoimmune and neurodegenerative diseases |
Japan Tobacco Inc. |
Metrion Biosciences Ltd. |
Payment unspecified |
1/29/18 |
JSR to grant bacterial targets rights to Biomx to develop and commercialize phage therapies including BX-002 against IBD |
JSR Corp. |
Biomx Ltd. |
Payment unspecified |
1/30/18 |
Innate Pharma and Medimmune to evaluate safety and efficacy of durvalumab in combination with IPH-5401 for solid tumors |
Medimmune LLC |
Innate Pharma SA |
Unknown |
1/30/18 |
Bridgebio to develop Novartis' infigratinib for cholangiocarcinoma |
Novartis AG |
Bridgebio Pharma |
Payment unspecified |
1/30/18 |
Oncovir to manufacture and supply Hiltonol to Genocea for research, development and commercialization of products with Genocea's technology worldwide |
Oncovir Inc. |
Genocea Biosciences Inc. |
Payment unspecified |
1/26/18 |
Pernix Therapeutics to settle patent litigation with Actavis for the generic version of Zohydro in the U.S. |
Pernix Therapeutics Holdings Inc. |
Actavis Inc. |
Payment unspecified |
1/29/18 |
Canbridge to develop and commercialize Puma's Nerlynx against cancer in mainland China, Taiwan, Hong Kong and Macau |
Puma Biotechnology Inc. |
Canbridge Life Sciences Ltd. |
$255.00 |
1/30/18 |
Medison to commercialize Puma Biotechnology's Nerlynx against HER2-positive breast cancer in Israel |
Puma Biotechnology Inc. |
Medison Pharma Ltd. |
Payment unspecified |
1/30/18 |
Casi acquires an abbreviated new drug application portfolio from Sandoz |
Sandoz Inc. |
Casi Pharmaceuticals Inc. |
$18.00 |
1/26/18 |
Beijing to develop Sinocelltech's 14-valent human papillomavirus vaccine |
Sinocelltech Ltd. |
Beijing Nuonin Sci&Tech Co. Ltd. |
Payment unspecified |
1/26/18 |
Wuxi Biologics to manufacture Aravive Biologics' AVB-S6-500 for clinical trials |
Wuxi Biologics |
Aravive Biologics Inc. |
Payment unspecified |
1/29/18 |
February | ||||
Immunobiochem to develop antibody drug conjugates using APC's site-selective conjugation technology against triple-negative breast cancer |
Advanced Proteome Therapeutics Inc. |
Immunobiochem Corp. |
Payment unspecified |
2/7/18 |
AGC Biologics to manufacture Catalyst Biosciences's CB-2679d for hemophilia B |
AGC Biologics |
Catalyst Biosciences Inc. |
Payment unspecified |
2/26/18 |
AGC Biologics to manufacture Allergy Therapeutics' Polyvac Peanut for clinical studies |
AGC Biologics |
Allergy Therapeutics plc |
Payment unspecified |
2/28/18 |
Albumedix and Hookipa Biotech to develop HB-101 vaccine for cytomegalovirus infection using Recombumin technology |
Albumedix A/S |
Hookipa Biotech AG |
Payment unspecified |
2/12/18 |
Albumedix and Savara to develop Molgradex for severe lung disease including acute respiratory distress syndrome using Recombumin technology |
Albumedix A/S |
Savara Inc. |
Payment unspecified |
2/12/18 |
Albumedix and Merck to develop Proquad for varicella virus infection and M-M-R-II for measles, mumps and rubella virus infection using recombumin technology |
Albumedix A/S |
Merck & Co. Inc. |
Payment unspecified |
2/12/18 |
Janssen to develop novel immune-modulating drugs and to advance Aldeyra's reproxalap analogs systemic inflammatory diseases |
Aldeyra Therapeutics Inc. |
Janssen Research & Development LLC |
Payment unspecified |
2/27/18 |
Amerisourcebergen to provide pharmacy services for Emmaus Medical's Endari against sickle cell disease |
Amerisourcebergen Drug Corp. |
Emmaus Medical Inc. |
Payment unspecified |
2/9/18 |
Celgene to use Amunix XTEN and ProTIA technology for discovery and development of therapeutics against specified targets |
Amunix Inc. |
Celgene Corp. |
Payment unspecified |
2/20/18 |
Deqi and Antengene to develop CC-223 against cancer |
Antengene Corp. |
Deqi (Zhejiang) Pharmaceutical Technology Co. Ltd. |
Unknown |
2/2/18 |
Aridis and Shenzhen to establish a joint venture to develop and market MAb therapies for acute pneumonia in China |
Aridis Pharmaceuticals Inc. |
Shenzhen Hepalink Pharmaceutical Group Co. Ltd. |
Unknown |
2/27/18 |
Sinovant Sciences to develop and commercialize Arqule's derazantinib in China, Hong Kong, Macau and Taiwan |
Arqule Inc. |
Sinovant Sciences Ltd. |
$87.50 |
2/2/18 |
Aspire to provide manufacturing services for Hemostemix's ACP-01 phase II against critical limb ischemia |
Aspire Health Science LLC |
Hemostemix Inc. |
Payment unspecified |
2/22/18 |
Just Biotherapeutics and Atum to accelerate drug discovery using Leap-In Transposase technology and cell line development tools |
Atum |
Just Biotherapeutics |
Payment unspecified |
2/21/18 |
Avadel Pharmaceuticals to develop four product formulations using Liquitime technology for Cerecor |
Avadel Pharmaceuticals plc |
Cerecor Inc. |
$1.00 |
2/12/18 |
Cerecor to acquire Avadel Pharmaceuticals' four pediatric commercial-stage assets |
Avadel Pharmaceuticals plc |
Cerecor Inc. |
Payment unspecified |
2/12/18 |
Oncologie to acquire assets related to Avid's phosphatidylserine-targeting program including bavituximab |
Avid Bioservices Inc. |
Oncologie Inc. |
$103.00 |
2/12/18 |
Bavarian and Astrazeneca to evaluate CV-301 in combination with durvalumab for metastatic colorectal and pancreatic cancers |
Bavarian Nordic A/S |
Astrazeneca plc |
Payment unspecified |
2/26/18 |
Takeda to leverage Beacon Discovery's GPCR based drug discovery expertise to identify drug candidates for a range of gastrointestinal disorders, worldwide |
Beacon Discovery Inc. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
2/27/18 |
Whanin to commercialize Bial's Zebinix for partial-onset seizures in South Korea |
Bial Group |
Whanin Pharmaceutical Co. Ltd. |
Payment unspecified |
2/26/18 |
Sensus and Birchbiomed to develop FS-2 by integrating with SRT for keloids scars |
Birchbiomed Inc. |
Sensus Healthcare |
Payment unspecified |
2/5/18 |
CSBio to manufacture Arch's Metablok for inflammation injury, sepsis and cancer metastasis |
CSBio Co. |
Arch Biopartners Inc. |
Payment unspecified |
2/27/18 |
Hemacare to integrate its PBMCs into Charles River's NCG/PBMC select humanization kit for infectious disease and immuno-oncology research |
Charles River Laboratories International Inc |
Hemacare Corp. |
Payment unspecified |
2/6/18 |
Cipla to promote and distribute Roche's tocilizumab and Avastin in India |
Cipla Ltd. |
Roche Holding AG |
Payment unspecified |
2/27/18 |
Pharmascience to develop and supply Cosmo's Eleview, Methylene Blue MMX, Rifamycin SV MMX and Qolotag in Canada for gastrointestinal disorders |
Cosmo Pharmaceuticals SpA |
Pharmascience Inc. |
$3.94 |
2/1/18 |
Vizient to award Crawford Healthcare a contract for touchless care Zinc protectant spray to treat incontinence associated dermatitis |
Crawford Healthcare Ltd. |
Vizient Inc. |
Payment unspecified |
2/1/18 |
Cryoport to provide cold chain logistics for clinical trials of Tigenix's Cx-611 against sepsis |
Cryoport Inc. |
Tigenix NV |
Payment unspecified |
2/5/18 |
Kadmon to use Distributed Bio's Superhuman 2.0 antibody discovery platform |
Distributed Bio |
Kadmon Pharmaceuticals LLC |
Payment unspecified |
2/28/18 |
Emerge Health to commercialize Diurnal's Alkindi and Chronocort for adrenal insufficiency and congenital adrenal hyperplasia in Australia and New Zealand |
Diurnal Ltd. |
Emerge Health Pty. Ltd. |
Payment unspecified |
2/19/18 |
Dyadic and an undisclosed biotech company to produce an active moiety in C1 |
Dyadic International Inc. |
Undisclosed |
Payment unspecified |
2/7/18 |
Mitsubishi and Dyadic to explore the C1 technology to produce two vital therapeutic proteins |
Dyadic International Inc. |
Mitsubishi Chemical Holdings Corp. |
Payment unspecified |
2/27/18 |
THEA (Therapeutique et Applications) to develop and commercialize Elsalys Biotech's ELB-011 against ophthalmology |
Elsalys Biotech |
THEA (Therapeutique et Applications) SA |
Payment unspecified |
2/22/18 |
Emulate and Roche for efficacy and safety of new antibody therapeutics and combination therapies using Human Emulation System |
Emulate Inc. |
F. Hoffmann-La Roche AG |
Payment unspecified |
2/20/18 |
Fujifilm and Takeda to develop iPSC-based cardiomyocytes for heart failure worldwide |
Fujifilm Holdings Corp. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
2/8/18 |
Shanghai Henlius to develop and commercialize Galaxy Biotech's MAb targeting death-receptor pathway for cancer in China mainland, Hong Kong, Macao and Taiwan |
Galaxy Biotech LLC |
Shanghai Henlius Biotech Co. Ltd. |
Payment unspecified |
2/12/18 |
Lee's Pharmaceutical to develop and commercialize GC Pharma's GCC-4401C for thromboembolic disease in China and South East Asia |
GC Pharma |
Lee's Pharmaceutical Holdings Ltd. |
Payment unspecified |
2/13/18 |
Aspire to commercialize Hemostemix's ACP-01 in Bahamas, Costa Rica, Dominican Republic, Mexico, Panama and Florida state against various indications |
Hemostemix Inc. |
Aspire Health Science LLC |
Payment unspecified |
2/23/18 |
Horizon Discovery and an undisclosed partner to develop and manufacture new biomanufacturing cell line for commercial use using Horizon's technologies |
Horizon Discovery Group plc |
Undisclosed |
Payment unspecified |
2/12/18 |
Albumedix and Immunocore to develop IMCgp100 for uveal melanoma |
Immunocore Ltd. |
Albumedix A/S |
Payment unspecified |
2/12/18 |
Servier to develop Immunoqure's human Interferon, an autoantibody for systemic lupus erythemathosus and Sjögren's syndrome, worldwide |
Immunoqure AG |
Servier |
$193.16 |
2/6/18 |
Stemnovate to acquire iPS Academia's patents related to iPS cell technologies |
iPS Academia Japan Inc. |
Stemnovate Ltd. |
Payment unspecified |
2/19/18 |
Scancell to use ISA's Amplivant adjuvant technology to manufacture, develop and commercialize Modi-1 for cancer worldwide |
ISA Pharmaceuticals BV |
Scancell Ltd. |
Payment unspecified |
2/15/18 |
ITM to supply Endocyte with no-carrier-added lutetium, Endolucinbeta, for use in phase III clinical trail of 177Lu-PSMA-617 for prostate cancer |
Isotopen Technologien München AG |
Endocyte Inc. |
Payment unspecified |
2/26/18 |
Sierra and Janssen to evaluate niraparib and SRA-737 combination against metastatic castration-resistant prostate cancer |
Janssen Research & Development LLC |
Sierra Oncology Inc. |
Payment unspecified |
2/27/18 |
Sumitomo to develop and commercialize a substance using JCR's J-Brain Cargo BBB penetration technology for central nervous system diseases |
JCR Pharmaceuticals Co. Ltd. |
Sumitomo Dainippon Pharma Co. Ltd. |
$32.77 |
2/26/18 |
Jiangsu Aidea and Nanjing Ansailai to investigate ACC-007 for HIV infection |
Jiangsu Aidea Pharmaceutical Co. Ltd. |
Nanjing Ansailai Medical Technology Co. Ltd. |
Payment unspecified |
2/9/18 |
Valeant and Kaken to develop and commercialize products containing KP-470 for dermatological and rheumatological disorders in the U.S., Canada, and Western and Eastern Europe |
Kaken Pharmaceutical Co. Ltd. |
Valeant Pharmaceuticals International Inc. |
Payment unspecified |
2/27/18 |
Liaoning Green and Shanyang to develop MT-1207 tablets for an undisclosed indication in China |
Liaoning Green Biological Pharmaceutical Group Co. Ltd. |
Shenyang Neptunus Biotechnology Co. Ltd. |
Unknown |
2/11/18 |
Cullinan to develop novel agonistic antibody therapeutics using MABD's unique discovery platform |
MAB Discovery GmbH |
Cullinan Oncology LLC |
Payment unspecified |
2/20/18 |
Cellsystems to distribute Minerva's Alphastem Naive Stem Cell Culture System in Europe |
Minerva Biotechnologies Corp. |
Cellsystems Biotechnologie Vertrieb GmbH |
Payment unspecified |
2/26/18 |
Oncologie to develop and commercialize Mologen's lefitolimod for immuno-oncology in China and other Asian countries |
Mologen AG |
Oncologie Inc. |
$123.67 |
2/13/18 |
Mylan to manufacture Santen's Thiola for cystine stone formation |
Mylan Inc. |
Santen Pharmaceutical Co. Ltd. |
Payment unspecified |
2/8/18 |
N4 Pharma and Medimmune to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec system |
N4 Pharma plc |
Medimmune LLC |
Payment unspecified |
2/2/18 |
Nektar and BMS to develop and commercialize NKTR-214 in combination with Opdivo and (Opdivo + Yervoy) against cancer worldwide |
Nektar Therapeutics |
Bristol-Myers Squibb Co. |
$3,630.00 |
2/13/18 |
Netvation DL Medicine to screen and develop chemical entities against Pfizer's pre-selected targets for multiple therapeutic areas |
Netvation DL Medicine |
Pfizer Inc. |
Payment unspecified |
2/6/18 |
Novoheart to test Sumocor's novel therapeutics for heart failure using Myheart Platform |
Novoheart Holdings Ltd. |
Sumocor LLC |
Payment unspecified |
2/14/18 |
Bioverativ and Oxford Biomedica to develop and manufacture lentiviral vectors for haemophilia using Lentivector Enabled and manufacturing technology |
Oxford Biomedica plc |
Bioverativ Inc. |
$105.00 |
2/15/18 |
Pharmabcine and Merck to evaluate the combination of TTAC-0001 with Keytruda against recurrent glioblastoma multiforme and triple-negative breast cancer |
Pharmabcine |
Merck & Co. Inc. |
Payment unspecified |
2/1/18 |
Seattle Genetics to develop and commercialize Pharmamar's ADCs worldwide |
Pharmamar Inc. |
Seattle Genetics Inc. |
$5.00 |
2/14/18 |
Argos to obtain option to use and evaluate Pharmstandard's human anti-PD1 MAbs and related technology for cancer in the U.S. and Canada |
Pharmstandard |
Argos Therapeutics GmbH |
$12.10 |
2/1/18 |
Seattle to use Pieris' Anticalin technology to develop novel Antibody-Anticalin fusion proteins for solid tumors and blood cancers worldwide |
Pieris Pharmaceuticals Inc. |
Seattle Genetics Inc. |
$1,230.00 |
2/8/18 |
Santhera to develop and commercialize Polyphor's POL-6014 against cystic fibrosis and other pulmonary diseases worldwide |
Polyphor Ltd. |
Santhera Pharmaceuticals AG |
$129.20 |
2/15/18 |
Roivant to develop and commercialize Poxel's imeglimin for metabolic disorders including type 2 diabetes in the U.S., Europe and all other countries excluding East and Southeast Asia |
Poxel SA |
Roivant Sciences Ltd. |
$675.00 |
2/12/18 |
Mylan and Revance Therapeutics to develop and commercialize Botox biosimilar for multiple indications worldwide excluding Japan |
Revance Therapeutics Inc. |
Mylan Inc. |
$350.00 |
2/28/18 |
Zhejiang Haichang to develop Rexahn's RX-0201 using Qtsome technology for hepatocellular carcinoma |
Rexahn Pharmaceuticals Inc. |
Zhejiang Haichang Biotechnology Co. Ltd. |
$10.00 |
2/8/18 |
Sangamo and Kite Pharma to develop and commercialize engineered cell therapies for cancer worldwide using ZFN technology |
Sangamo Therapeutics Inc. |
Kite Pharma Inc. |
$3,160.00 |
2/20/18 |
Partner Therapeutics acquires worldwide rights to develop and commercialize Sanofi's Leukine |
Sanofi SA |
Partner Therapeutics |
Payment unspecified |
2/1/18 |
Sanofi and Roche to research atezolizumab in combination with isatuximab in certain solid tumors |
Sanofi SA |
Roche Holding AG |
Unknown |
2/7/18 |
Anabios and Sanofi to develop new ion channel modulators using Cardioprime technology for atrial fibrillation worldwide |
Sanofi SA |
Anabios Corp. |
Payment unspecified |
2/8/18 |
Pfizer to distribute Santen's Thiola for cystine stone formation in Japan |
Santen Pharmaceutical Co. Ltd. |
Pfizer Japan Inc. |
Payment unspecified |
2/8/18 |
Eurofins Biopharma to distribute Senzagen's GARD test for allergy worldwide |
Senzagen AB |
Eurofins Biopharma Product Testing Munich GmbH |
Payment unspecified |
2/16/18 |
Biosciences and Mab-Venture to develop and manufacture multiple undisclosed biosimilars worldwide |
Shanghai Mab-Venture Biomedical Co. Ltd. |
Biosciences Corp. |
Payment unspecified |
2/10/18 |
Sirenas and BMS to identify drug candidates against therapeutic targets |
Sirenas Marine Discovery LLC |
Bristol-Myers Squibb Co. |
Payment unspecified |
2/12/18 |
Daré Bioscience to develop Strategic Science & Technologies' SST-6007 against female sexual arousal disorder |
Strategic Science & Technologies LLC |
Daré Bioscience Inc. |
Payment unspecified |
2/12/18 |
Syndax and Astrazeneca to evaluate the safety and efficacy of a combination of SNDX-6352 with durvalumab in solid tumors |
Syndax Pharmaceuticals Inc. |
Astrazeneca plc |
Payment unspecified |
2/1/18 |
C3J to acquire SGI's engineered bacteriophage platform for integration with R&D programs |
Synthetic Genomics Inc. |
C3J Therapeutics Inc. |
Payment unspecified |
2/28/18 |
Nipro and TC Biopharm to co-develop Gamma-Delta CAR-T immunotherapy for cancer and viral disease, with worldwide commercialization rights for Nipro |
TC Biopharm Ltd. |
Nipro Corp. |
Payment unspecified |
2/7/18 |
Tesaro and Genentech to evaluate combination of Tecentriq and Zejula for metastatic bladder cancer |
Tesaro Inc. |
Genentech Inc. |
Unknown |
2/26/18 |
Tetragenetics and an undisclosed biotech company to collaborate on the discovery of drug candidates using Tetraexpress platform technology |
Tetragenetics Inc. |
Undisclosed |
$300.00 |
2/13/18 |
Everest to develop and commercialize Tetraphase's eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea and Singapore |
Tetraphase Pharmaceuticals Inc. |
Everest Medicines |
$43.50 |
2/20/18 |
Janssen and Theravance to co-develop and commercialize TD-1473 and related back-up compounds for inflammatory intestinal diseases worldwide |
Theravance Biopharma Inc. |
Janssen Biotech Inc. |
$1,000.00 |
2/7/18 |
Tychan and Wuxi Biologics to develop tyzivumab for Zika virus infection |
Tychan Pte. Ltd. |
Wuxi Biologics |
Payment unspecified |
2/8/18 |
Undisclosed major antibody drug conjugate biopharmaceutical company to assess Spring Bank's SB-1128 against cancer |
Undisclosed |
Spring Bank Pharmaceuticals Inc. |
Payment unspecified |
2/20/18 |
Zealand Pharma and Uniquest to develop venom-derived peptide therapeutics for gastrointestinal and metabolic diseases |
Uniquest Pty. Ltd. |
Zealand Pharma A/S |
Payment unspecified |
2/20/18 |
Veritas Pharma to sign a memorandum of understanding with Biocan to further investigate of cannabis strains |
Veritas Pharma Inc. |
Biocan Technologies Inc. |
Payment unspecified |
2/28/18 |
Abbvie and Voyager to develop and commercialize vectorized MAbs against tau for Alzheimer's disease and other neurodegenerative diseases, worldwide |
Voyager Therapeutics |
Abbvie Inc. |
$1,179.00 |
2/16/18 |
Wave Life Sciences and Takeda to discover, develop and commercialize antisense oligonucleotides for central nervous system disease worldwide |
Wave Life Sciences Ltd. |
Takeda Pharmaceutical Co. Ltd. |
$2,230.00 |
2/19/18 |
CR Pharma to develop and commercialize Xbrane's Spherotide in China |
Xbrane Biopharma AB |
CR Pharma |
Payment unspecified |
2/6/18 |
Zhaoke and Haimen Wisdom to develop tekafalin sodium for an unidentified indication in China |
Zhaoke Pharmaceutical (Guangzhou) Co. Ltd. |
Haimen Wisdom Pharmaceutical Co. Ltd. |
Unknown |
2/13/18 |
March | ||||
Recipharm to use Altus Formulation's drug delivery technologies and products |
Altus Formulation Inc. |
Recipharm AB |
Payment unspecified |
3/5/18 |
OHM to develop and commercialize Aptose's APL-581, as well as a related BET protein and kinase inhibitor program for cancer worldwide |
Aptose Biosciences Inc. |
OHM Oncology |
$125.00 |
3/7/18 |
Avid to provide process development and clinical manufacturing services for Acumen's ACU-193 against Alzheimer's disease |
Avid Bioservices Inc. |
Acumen Pharmaceuticals Inc. |
Payment unspecified |
3/1/18 |
HRA Pharma acquires Lysodren from BMS |
Bristol-Myers Squibb Co. |
HRA Pharma |
Payment unspecified |
3/14/18 |
Redwood Pharma acquires Capavision's IP to develop RP-101 against chronic dry eye disease |
Capavision Ltd. |
Redwood Pharma AB |
$0.62 |
3/8/18 |
Biodesix to develop Checkmate's CMP-001 in combination with pembrolizumab using Diagnostic Cortex biomarker discovery platform for cancer |
Checkmate Pharmaceuticals |
Biodesix Inc. |
Payment unspecified |
3/20/18 |
Fosun Pharma to develop and distribute Dova Pharmaceuticals' avatrombopag against thrombocytopenia in mainland China and Hong Kong |
Dova Pharmaceuticals Inc. |
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. |
Payment unspecified |
3/16/18 |
Leniobio to utilize Dow Agrosciences' proprietary eukaryotic cell-free protein expression technology |
Dow Agrosciences LLC |
Leniobio GmbH |
Payment unspecified |
3/15/18 |
Merck and Eisai to jointly develop and commercialize Lenvima as monotherapy and in combination with Keytruda for multiple cancer types worldwide |
Eisai Co. Ltd. |
Merck & Co. Inc. |
$5,755.00 |
3/7/18 |
Guangdong Zhongsheng Pharma and Wuxi Apptec to develop ZSP-1241 for cancers in China |
Guangdong Zhongsheng Pharmaceutical Co. Ltd. |
Wuxi Pharmatech (Cayman) Inc. |
Payment unspecified |
3/6/18 |
Magenta to develop and commercialize multi-target antibody drug conjugates using Heidelberg's ATAC platform for cancer and bone marrow transplantation worldwide |
Heidelberg Pharma Holding GmbH |
Magenta Therapeutics Inc. |
$334.00 |
3/5/18 |
Hemogenyx and an undisclosed biotech company to develop humanized mice as a tool for drug development and testing |
Hemogenyx Pharmaceuticals Ltd. |
Undisclosed |
$0.25 |
3/13/18 |
Hitachi Chemical to provide manufacturing and development services for Sanbio's SB-623 |
Hitachi Chemical Co. Ltd. |
Sanbio Co. Ltd. |
Payment unspecified |
3/13/18 |
Immutep and Merck to evaluate the combination of IMP-321 and Keytruda in different solid tumors |
Immutep Ltd. |
Merck & Co. Inc. |
Unknown |
3/11/18 |
Insud Pharma to distribute Pharco's ravidasvir along with sofosbuvir for hepatitis C in Latin America |
Insud Pharma |
Pharco Pharmaceuticals Inc. |
Payment unspecified |
3/5/18 |
IO Biotech and Merck to conduct a phase I/II trial evaluating IO-102 in combination with Keytruda for metastatic non-small cell lung cancer |
IO Biotech ApS |
Merck & Co. Inc. |
Payment unspecified |
3/12/18 |
Platelet Biogenesis to use iPS Academia's patents covering iPS cell-derived platelet products for human regenerative therapy |
iPS Academia Japan Inc. |
Platelet Biogenesis |
Payment unspecified |
3/15/18 |
Rohto to develop and commercialize JT's JTE-052 for ophthalmological diseases in Japan |
Japan Tobacco Inc. |
Rohto Pharmaceutical Co. Ltd. |
Payment unspecified |
3/15/18 |
Pharmaceutical Associates to repack and distribute Lannett's five currently marketed products in U.S. |
Lannett Co. Inc. |
Pharmaceutical Associates Inc. |
Payment unspecified |
3/12/18 |
Undisclosed company to distribute Lannett's generic Diclofenac ER and Fluvastatin ER in the U.S. |
Lannett Co. Inc. |
Undisclosed |
Payment unspecified |
3/12/18 |
Karo Pharma acquires Leo Pharma's product portfolio including 10 products indicated for infection, cardiovascular and dermatological disorders |
Leo Pharma A/S |
Karo Pharma AB |
$306.22 |
3/5/18 |
Roivant to develop and commercialize Ligand's LGD-6972 for type 1 and type 2 diabetes worldwide |
Ligand Pharmaceuticals Inc. |
Roivant Sciences Ltd. |
$533.80 |
3/5/18 |
LTS to manufacture Intec Pharma's AP-CD/LD against Parkinson's disease |
Lohmann Therapie-Systeme GmbH & Co. KG |
Intec Pharma Ltd. |
Payment unspecified |
3/12/18 |
Medimetriks to divest U.S. rights for Xepi against impetigo to Cutanea Life Sciences |
Medimetriks Pharmaceuticals Inc. |
Cutanea Life Sciences Inc. |
$30.00 |
3/5/18 |
Mingju and JW Therapeutics to develop JWCAR-029 for non-Hodgkin lymphoma |
Mingju Therapeutics (Shanghai) Co. Ltd. |
JW Therapeutics (Shanghai) Co. Ltd. |
Payment unspecified |
3/7/18 |
Dare to develop Orbis's ORB-204 and ORB-214 for contraception with an option for worldwide rights |
Orbis Biosciences Inc. |
Dare Bioscience Inc. |
Payment unspecified |
3/12/18 |
Avillion and Pearl Therapeutics to develop PT-027 for asthma worldwide |
Pearl Therapeutics Inc. |
Avillion LLP |
Payment unspecified |
3/13/18 |
Biogen to acquire Pfizer's PF-04958242 for cognitive impairment associated with schizophrenia |
Pfizer Inc. |
Biogen Inc. |
$590.00 |
3/12/18 |
Pharaon to distribute Amryt Pharma's lomitapide for homozygous familial hypercholesterolaemia in Lebanon, Jordan and Syria |
Pharaon Group |
Amryt Pharma plc |
Payment unspecified |
3/6/18 |
Prothena and Celgene to develop and commercialize antibodies targeting tau, TDP-43 and an undisclosed target against neurodegenerative diseases worldwide |
Prothena Corp plc |
Celgene Corp. |
$2,262.50 |
3/20/18 |
Selcia and Cresset to discover novel molecules against Parkinson's disease |
Selcia Ltd. |
Cresset |
Unknown |
3/8/18 |
Compugen to use Selexis' SURE technology and COM-701 to develop antibody-based therapeutics targeting certain cancers |
Selexis SA |
Compugen Ltd. |
Payment unspecified |
3/7/18 |
Caladrius to acquire rights to the CD34+ cell therapy program for refractory angina worldwide |
Shire plc |
Caladrius Biosciences Inc. |
Payment unspecified |
3/6/18 |
Lupin and CSIR-NCL to develop a continuous manufacturing process for a biosimilar monoclonal antibody therapeutic |
The National Chemical Laboratories |
Lupin Ltd. |
Payment unspecified |
3/8/18 |
Vividion and Celgene to discover and develop small molecules against targets for oncology, inflammatory and neurodegenerative indications using Vividion's platform worldwide |
Vividion Therapeutics Inc. |
Celgene Corp. |
$101.00 |
3/5/18 |
Eleison to jointly evaluate the feasibility of using Windtree's ADS to deliver ILC in combination with KL4 surfactant |
Windtree Therapeutics Inc. |
Eleison Pharmaceuticals Inc. |
Payment unspecified |
3/12/18 |
Asahi Kasei to reformulate its products using Xeris' Xeriject technology |
Xeris Pharmaceuticals Inc. |
Asahi Kasei Pharma Corp. |
Payment unspecified |
3/13/18 |
Medison Pharma to commercialize Zambon's Xadago for Parkinson's disease in Israel |
Zambon Co. SpA |
Medison Pharma Ltd. |
Payment unspecified |
3/1/18 |
Medicure to commercialize Zydus-Cadila's pitavastatin against hypercholesterolemia in the U.S. |
Zydus-Cadila Group |
Medicure Inc. |
Payment unspecified |
3/7/18 |
|
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. | ||||